Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000962:Antimalarials / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D006918:Hydroxyurea / Q000627:therapeutic use*; D015141:Los Angeles; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use*; D018579:Patient Selection
D019380:Anti-HIV Agents; D000962:Antimalarials; D019384:Nucleic Acid Synthesis Inhibitors; D006886:Hydroxychloroquine; D016049:Didanosine; D006918:Hydroxyurea